Germany has shifted from a market where the pharmaceutical industry could enjoy considerable pricing freedom to a sensitive market influenced by cost-containment policies. However, pressure is being placed upon the country to change its pricing policy once again. Aug 6, 2012 By:Nathan Jessop
Germany has shifted from relative pricing freedom to a market that is sensitive and influenced by cost-containment policies. But pharma is pressuring the country to change its policy again.